vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and CVR ENERGY INC (CVI). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $1.8B, roughly 1.5× CVR ENERGY INC). Bausch Health Companies Inc. runs the higher net margin — -3.7% vs -6.1%, a 2.4% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs -7.0%). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs -1.4%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
CVR Energy Inc is a United States-based energy holding company operating two core segments: petroleum refining and nitrogen fertilizer manufacturing. It produces a wide range of products including gasoline, diesel, jet fuel, and agricultural fertilizers, primarily serving commercial, industrial and agricultural customers across North America.
BHC vs CVI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $1.8B |
| Net Profit | $-103.0M | $-110.0M |
| Gross Margin | — | -3.1% |
| Operating Margin | 17.0% | -5.3% |
| Net Margin | -3.7% | -6.1% |
| Revenue YoY | 9.3% | -7.0% |
| Net Profit YoY | -205.1% | -492.9% |
| EPS (diluted) | $-0.30 | $-1.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $1.8B | ||
| Q3 25 | $2.7B | $1.9B | ||
| Q2 25 | $2.5B | $1.8B | ||
| Q1 25 | $2.3B | $1.6B | ||
| Q4 24 | $2.6B | $1.9B | ||
| Q3 24 | $2.5B | $1.8B | ||
| Q2 24 | $2.4B | $2.0B | ||
| Q1 24 | $2.2B | $1.9B |
| Q4 25 | $-103.0M | $-110.0M | ||
| Q3 25 | $179.0M | $374.0M | ||
| Q2 25 | $148.0M | $-114.0M | ||
| Q1 25 | $-58.0M | $-123.0M | ||
| Q4 24 | $98.0M | $28.0M | ||
| Q3 24 | $-85.0M | $-124.0M | ||
| Q2 24 | $10.0M | $21.0M | ||
| Q1 24 | $-64.0M | $82.0M |
| Q4 25 | — | -3.1% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | -3.7% | ||
| Q1 25 | — | -5.5% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | — | -3.9% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | 8.6% |
| Q4 25 | 17.0% | -5.3% | ||
| Q3 25 | 23.1% | 26.3% | ||
| Q2 25 | 17.5% | -5.8% | ||
| Q1 25 | 12.2% | -8.0% | ||
| Q4 24 | 21.8% | 1.1% | ||
| Q3 24 | 12.7% | -6.2% | ||
| Q2 24 | 16.2% | 1.4% | ||
| Q1 24 | 13.1% | 6.6% |
| Q4 25 | -3.7% | -6.1% | ||
| Q3 25 | 6.7% | 19.2% | ||
| Q2 25 | 5.8% | -6.5% | ||
| Q1 25 | -2.6% | -7.5% | ||
| Q4 24 | 3.8% | 1.4% | ||
| Q3 24 | -3.4% | -6.8% | ||
| Q2 24 | 0.4% | 1.1% | ||
| Q1 24 | -3.0% | 4.4% |
| Q4 25 | $-0.30 | $-1.09 | ||
| Q3 25 | $0.48 | $3.72 | ||
| Q2 25 | $0.40 | $-1.14 | ||
| Q1 25 | $-0.16 | $-1.22 | ||
| Q4 24 | $0.24 | $0.28 | ||
| Q3 24 | $-0.23 | $-1.24 | ||
| Q2 24 | $0.03 | $0.21 | ||
| Q1 24 | $-0.17 | $0.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $511.0M |
| Total DebtLower is stronger | $20.8B | $1.8B |
| Stockholders' EquityBook value | $-554.0M | $730.0M |
| Total Assets | $26.4B | $3.7B |
| Debt / EquityLower = less leverage | — | 2.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $511.0M | ||
| Q3 25 | $1.3B | $670.0M | ||
| Q2 25 | $1.7B | $596.0M | ||
| Q1 25 | $1.1B | $695.0M | ||
| Q4 24 | $1.2B | $987.0M | ||
| Q3 24 | $719.0M | $534.0M | ||
| Q2 24 | $595.0M | $586.0M | ||
| Q1 24 | $733.0M | $644.0M |
| Q4 25 | $20.8B | $1.8B | ||
| Q3 25 | $21.0B | $1.8B | ||
| Q2 25 | $21.7B | $1.8B | ||
| Q1 25 | $21.5B | $1.9B | ||
| Q4 24 | $21.6B | $1.9B | ||
| Q3 24 | $21.5B | $1.6B | ||
| Q2 24 | $21.7B | $1.6B | ||
| Q1 24 | $22.1B | $1.6B |
| Q4 25 | $-554.0M | $730.0M | ||
| Q3 25 | $-565.0M | $840.0M | ||
| Q2 25 | $-764.0M | $466.0M | ||
| Q1 25 | $-1.2B | $580.0M | ||
| Q4 24 | $-1.3B | $703.0M | ||
| Q3 24 | $-1.2B | $675.0M | ||
| Q2 24 | $-1.2B | $849.0M | ||
| Q1 24 | $-1.1B | $879.0M |
| Q4 25 | $26.4B | $3.7B | ||
| Q3 25 | $26.8B | $4.0B | ||
| Q2 25 | $27.3B | $4.0B | ||
| Q1 25 | $26.4B | $4.3B | ||
| Q4 24 | $26.5B | $4.3B | ||
| Q3 24 | $26.5B | $3.9B | ||
| Q2 24 | $26.5B | $4.0B | ||
| Q1 24 | $26.9B | $4.1B |
| Q4 25 | — | 2.40× | ||
| Q3 25 | — | 2.17× | ||
| Q2 25 | — | 3.97× | ||
| Q1 25 | — | 3.29× | ||
| Q4 24 | — | 2.71× | ||
| Q3 24 | — | 2.33× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.79× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $0 |
| Free Cash FlowOCF − Capex | $403.0M | — |
| FCF MarginFCF / Revenue | 14.4% | — |
| Capex IntensityCapex / Revenue | 3.3% | 3.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $0 | ||
| Q3 25 | $405.0M | $163.0M | ||
| Q2 25 | $289.0M | $176.0M | ||
| Q1 25 | $211.0M | $-195.0M | ||
| Q4 24 | $601.0M | $98.0M | ||
| Q3 24 | $405.0M | $48.0M | ||
| Q2 24 | $380.0M | $81.0M | ||
| Q1 24 | $211.0M | $177.0M |
| Q4 25 | $403.0M | — | ||
| Q3 25 | $314.0M | $125.0M | ||
| Q2 25 | $190.0M | $135.0M | ||
| Q1 25 | $96.0M | $-246.0M | ||
| Q4 24 | $495.0M | $43.0M | ||
| Q3 24 | $334.0M | $14.0M | ||
| Q2 24 | $302.0M | $38.0M | ||
| Q1 24 | $129.0M | $130.0M |
| Q4 25 | 14.4% | — | ||
| Q3 25 | 11.7% | 6.4% | ||
| Q2 25 | 7.5% | 7.7% | ||
| Q1 25 | 4.2% | -14.9% | ||
| Q4 24 | 19.3% | 2.2% | ||
| Q3 24 | 13.3% | 0.8% | ||
| Q2 24 | 12.6% | 1.9% | ||
| Q1 24 | 6.0% | 7.0% |
| Q4 25 | 3.3% | 3.0% | ||
| Q3 25 | 3.4% | 2.0% | ||
| Q2 25 | 3.9% | 2.3% | ||
| Q1 25 | 5.1% | 3.1% | ||
| Q4 24 | 4.1% | 2.8% | ||
| Q3 24 | 2.8% | 1.9% | ||
| Q2 24 | 3.2% | 2.2% | ||
| Q1 24 | 3.8% | 2.5% |
| Q4 25 | — | — | ||
| Q3 25 | 2.26× | 0.44× | ||
| Q2 25 | 1.95× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.13× | 3.50× | ||
| Q3 24 | — | — | ||
| Q2 24 | 38.00× | 3.86× | ||
| Q1 24 | — | 2.16× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
CVI
| Petroleum Segment | $1.6B | 91% |
| Product UAN | $64.0M | 4% |
| Product Ammonia | $51.0M | 3% |
| Renewables Diesel | $27.0M | 1% |
| Product Urea Products | $8.0M | 0% |
| Renewable Fuel Credits | $7.0M | 0% |
